# US 2006/0052368 A1 · Aryl-substituted diazabicycloalkanes as nicotinic acetylcholine agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0052368 A1
- Document ID: US20060052368A1
- Status: Published application
- Kind: A1
- Application number: 10/524,482
- Filed: 2003-08-13
- Published: 2006-03-09
- Earliest claimed: 2002-08-14
- Inventors: Glen Ernst; Eifion Phillips; Richard Schmiesing
- Web page: https://patentgrep.com/patent/US20060052368A1

## CPC

- C07D 471/08: Bridged systems
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/34: Tobacco-abuse
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Nicotinic acetylcholine receptor agonists of formula I wherein a, b, c, D and R are as defined in the specification, enantiomers, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.

## Claims

### Claim 1

A compound of formula I:
wherein:
a, b and c are each 1 or 2;
D is oxygen or sulfur, and
R is selected from moieties of formulae II, III or IV:
wherein
R1, and R2 are independently selected from hydrogen, CN, CF3, halogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl or CO2R3;
Ar is phenyl, or
Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or
Ar is an 8-, 9- or 10-membered fused aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or
Ar is an 8-, 9- or 10-membered aromatic carbocyclic ring,
wherein said phenyl, heterocyclic rings or carbocyclic rings have 0, 1 or more substituents independently selected from hydrogen, CN, NO2, CF3, halogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, aryl, heteroaryl, OR3, CO2R3 or NR3R4; where
R3 and R4 are independently at each occurrence selected from hydrogen, C1-4alkyl, aryl, heteroaryl, C(O)R5, C(O)NHR5, CO2R5, SO2R6, or
R3, R4 and N in combination in the substituent —NR3R4 is (CH2)jQ(CH2)k where Q is O, S, NR5, or a bond; j is 2, 3 or 4 and k is 0, 1 or 2; wherein
R5 at each occurrence is independently selected from hydrogen, C1-4alkyl, aryl, or heteroaryl, and
R6 at each occurrence is independently selected from C1-4alkyl, aryl, or heteroaryl; or an enantiomer or pharmaceutically-acceptable salt thereof.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein D is oxygen.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein a is 1, b is 2 and c is 1, or an enantiomer or pharmaceutically-acceptable salt thereof.

### Claim 4 (depends on 1)

A compound of claim 1, wherein
Ar is phenyl, or
Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1 or 2 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur;
or an enantiomer or pharmaceutically-acceptable salt thereof.

### Claim 5 (depends on 4)

A compound according to claim 4, wherein Ar is a phenyl, furanyl or thiophenyl; or an enantiomer or pharmaceutically-acceptable salt thereof.

### Claim 6 (depends on 1)

A compound according to claim 1, wherein:
a is 1;
b is 2;
c is 1;
D is oxygen;
R1 and R2 are hydrogen;
Ar is phenyl, or
Ar is a 5- or 6-membered aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or
Ar is an 8-, 9- or 10-membered fused aromatic heterocyclic moiety having 1, 2 or 3 heteroatoms selected from nitrogen, oxygen or sulfur where not more than one of said heteroatoms is oxygen or sulfur, or
Ar is an 8-, 9- or 10-membered aromatic carbocyclic ring;
or an enantiomer or pharmaceutically-acceptable salt thereof.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein:
Ar is selected from phenyl, 2-pyridyl, 3-pyridyl, or 4-pyridyl, 2-furanyl or 3-furanyl, 2-thienyl or 3-thienyl, benzofuran-2-yl; benzofuran-3-yl, benzo[b]thiophen-2-yl or benzo[b]thiophen-3-yl;
or an enantiomer or pharmaceutically-acceptable salt thereof.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein:
Ar is substituted with one or more substituents independently selected from CN, NO2, CF3, halogen, C1-4alkyl, C2-4alkenyl, C2-4alkynyl, aryl, heteroaryl, OR3, CO2R3 or NR3R4;
or an enantiomer or pharmaceutically-acceptable salt thereof.

### Claim 9 (depends on 1)

A compound according to claim 1 selected from:
(1,4-diazabicyclo[3.2.2]non-4-yl)(phenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(3-fluorophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-fluorophenyl)methanone;
(3-chlorophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(4-chlorophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(3,4-dichlorophenyl)methanone;
(3-bromophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(4-bromophenyl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(3-iodophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-iodophenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-trifluoromethylphenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-methoxyphenyl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(4-trifluoromethoxyphenyl)methanone;
(5-chlorofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-bromofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-iodoofuran-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-chlorothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-bromothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(5-iodoothiophen-2-yl)(1,4-diazabicyclo[3.2.2]non-4-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(naphthalen-2-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(benzofuran-2-yl)methanone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(benzo[b]thiophen-2-yl)methanone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-phenylpropenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-phenylpropynone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(furan-2-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(furan-3-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(thiophen-2-yl)propenone;
1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(thiophen-3-yl)propenone;
(1,4-diazabicyclo[3.2.2]non-4-yl)(furan-2-yl)methanone;
(E)-1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(furan-2-yl)propenone;
(E)-1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(thiophen-2-yl)propenone;
(E)-1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(2-methoxyphenyl)-propenone;
(E)-1-(1,4-diazabicyclo[3.2.2]non-4-yl)-3-(2-methylphenyl)propenone;
(1,4-diaza-bicyclo[3.2.2]non-4-yl)-(1H-indol-5-yl)-methanone;
(1,4-diaza-bicyclo[3.2.2]non-4-yl)-(methyl-1H-indol-2-yl)-methanone, and
(Z)-1-(1,4-diaza-bicyclo[3.2.2]non-4-yl)-2-fluoro-3-phenyl-propenone,
or an enantiomer or pharmaceutically-acceptable salt thereof.

### Claim at position 10

10-12. (canceled)

### Claim 13 (depends on 1)

A method of treatment or prophylaxis of psychotic disorders, intellectual impairment disorders, human diseases or conditions in which activation of the α7 nicotinic receptor is beneficial, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder, anxiety, schizophrenia, mania or manic depression, Parkinson's disease, Huntington's disease, Tourette's syndrome, neurodegenerative disorders in which there is loss of cholinergic synapse, jetlag, cessation of smoking, nicotine addiction including that resulting from exposure to products containing nicotine, pain, or ulcerative colitis which method comprises administering a therapeutically effective amount of a compound as defined in claim 1.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a compound of formula I, as defined in claim 1, together with at least one pharmaceutically-acceptable excipient or diluent.
